Puyallup, WA – Western IRB (WIRB), the world's largest provider of ethical research review serving 2,300 academic medical centers (AMCs) and hospitals, announced today an alliance with Huron, a global professional services firm serving the health care, higher education, life sciences, and commercial sectors.
WIRB’s and Huron’s combined strengths can help institutions improve the effectiveness of clinical research for the development of new pharmaceuticals and medical devices. The alliance will provide clients with a wide range of administrative and clinical services that are integrated with empowering technologies to ease the financial, regulatory, and operational responsibilities of performing essential clinical research.
“Today, a number of factors have combined to make the conduct of clinical research challenging for many AMCs, hospitals, and their researchers. These programs are facing a reduction in government-sponsored research grants, coupled with an increase in regulatory requirements,” said Donald Deieso, PhD, chairman and chief executive officer of WIRB-Copernicus Group. “They must respond by attracting external research funding, conducting research with improved financial management, and streamlining administrative burdens. By combining the extensive experience of WIRB and Huron in serving this community, we intend to provide comprehensive solutions that will have a positive impact for our clients at this important moment of change.”
Huron assists AMCs, cancer centers, health systems, and community hospitals in managing their research programs. Huron has helped 99 of the nation’s top 100 research universities and more than half of the largest U.S. health systems achieve meaningful improvements.
Currently, more than 70 percent of AMCs and hospitals in the U.S. have named WIRB as their IRB-of-record for industry-funded research and regulatory advice and oversight.
“WIRB is quite simply the most trusted independent IRB partner to academic medical centers and hospitals,” said Stuart Horowitz, PhD, MBA, president of institutions for WIRB-Copernicus Group. “WIRB’s gold standard reputation with institutions, coupled with its deeply connected client base of industry research partners, provides a tremendous platform upon which institutions can grow their research programs.
“When you combine WIRB’s capabilities with those of Huron, institutions now have a complete solution to address all their research administration challenges,” Horowitz added.
For more information about WIRB, visit www.wirb.com.
About Western IRB
Founded in 1968, was the first independent review board and the pioneer of ethical review. It is now the trusted partner for more than 2,300 institutions in the U.S. alone. Western IRB is a member of the WIRB-Copernicus IRB Group, one of the divisions of WCG, Inc. - the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs and institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining the highest standards of human subject protections.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.